Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2003

The Effects of Alternative-Site Blood Glucose Monitoring on
Testing Frequency, Pain Rating, and Glycosylated Hemoglobin
Nancy Bennion
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Human and Clinical Nutrition Commons, and the Pharmacology Commons

Recommended Citation
Bennion, Nancy, "The Effects of Alternative-Site Blood Glucose Monitoring on Testing Frequency, Pain
Rating, and Glycosylated Hemoglobin" (2003). All Graduate Theses and Dissertations. 5495.
https://digitalcommons.usu.edu/etd/5495

This Thesis is brought to you for free and open access by
the Graduate Studies at DigitalCommons@USU. It has
been accepted for inclusion in All Graduate Theses and
Dissertations by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

THE EFFECTS OF ALTERNATIVE-SITE BLOOD GLUCOSE MONITORING ON
TESTING FREQUENCY, PAIN RATING, AND
GL YCOSYLATED HEMOGLOBIN
by
Nancy Bennion

A thesis submitted in partial fulfillment
of the requirements for the degree
of
MASTER OF SCIENCE
111

Nutrition and Food Sciences

Approved:

UTAH STATE UNIVERSITY
Logan, Utah

2003

11

'

Copyright © Nancy Bennion 2004

Ill

ABSTRACT

'
The Effects of Alternative-site Blood Glucose Monitoring on Testing Frequency,
Pain Rating, and Glycosylated Hemoglobin

by

Nancy Bem1ion, Master of Science
Utah State University, 2004

Major Professor: Dr. Nedra Christensen
Department: Food and Nutrition Science

A crossover design study was conducted to determine if reducing pain, by using
alternative sites off the finger tip, would increase testing frequency and improve clinical
outcome as measured by glycosylated hemoglobin. Subjects with type I and type 2
diabetes tested with the FreeStyle alternative-site meter (group I) or tested with their
original meter (group 2). After 3 months the subjects used the alternate meter. Testing
frequency and blood glucose concentrations were recorded for the month before the study
began and monthly thereafter. Glycosylated hemoglobin was tested initially, at the
crossover point, and at study conclusion. Insulin users increased testing frequency from
2.4 to 3.0 tests per day. Testing frequency for non-insulin users remained the same at 1.5
tests per day. Testing frequency was essentially the same with the FreeStyle and the
original meters. The average hemoglobin Ale was 7.4% (standard deviation 1.5%)
initially, 7.3% (standard deviation 1.5%) at the crossover point, and 6.9% (standard
deviation 1.1 %) after 6 months. There was no significant difference in hemoglobin A I c

IV

measurements between meter types after 6 months. Thirteen months later a final
hemoglobin A 1c~testing frequency, and a questionnaire regarding meter preference and
pain rating were obtained. Seventy-four percent of participants preferred the alternativesite meter, which was rated as significantly (p < .05) less painful. Testing frequency
significantly improved (p = .001) while free strips were being provided. Testing
frequency 13 months later was not significantly different from the baseline (p = .101).
Hemoglobin A 1c was significantly lower 6 months after the study began (p = .000) and
13 months later (p = .008) at baseline.

(48 pages)
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CHAPTER I
GENERAL INTRODUCTION

Definition ofDiabetes Mellitus

Diabetes mellitus is a syndrome resulting in hyperglycemia secondary to lack of
insulin or impaired effectiveness of insulin. Insulin is the major hormone responsible for
promoting the uptake of glucose from the bloodstream into the many organ and tissue
cells of the body. As the effectiveness of insulin is diminished, blood glucose rises above
normal, physiologic levels. Distinct symptoms of diabetes include polydypsia,
polyphagia and polyuria.
Diabetes mellitus can be classified as insulin-dependent diabetes mellitus (type 1
DM) or non-insulin-dependent diabetes mellitus (type 2 DM). While both types of
diabetes mellitus have unique features and characteristics, treatment revolves around
achieving and maintaining blood glucose levels within normal limits. The overall goal
for both types is essentially normoglycemia.
Although hyperglycemia is the hallmark abnom1ality seen in people with diabetes
mellitus, other complications develop as the disease progresses. Complications include
diabetic ketoacidosis, neuropathy, retinopathy, and vascular disease. If complications
develop, physical and financial burdens increase.
Diabetes mellitus has been described as an epidemic. Diabetes mellitus is
expected to increase in incidence in the U.S. Boyle 1 et al. projected that by 2050 nearly
29 million Americans will be diagnosed with the disease. An increase in 18 million
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cases in a span of less than 50 years will likely result in a sharp rise in national
morbidity and m~rtality. Because diabetes is ever-increasing in the U.S., treatment of the
disease will have an ever-increasing impact on all Americans. As the number of people
with diabetes mellitus increases, the economic burden of the disease will become more
severe.
The Diabetes Control and Complications Trial (DCCT) proved that achieving
blood glucose leve ls with in a normal range reduced the complications associated with
diabetes.

2

It can be deduced that improved blood glucose control also results in less

economic burden of the disease. Therefore, treatment modalities that improve glucose
control and ultimately reduce the severity of the complications of diabetes mellitus have
become even more important.

Self Monitoring of Blood Glucose

Since the DCCT trial, guidelines for treatment and care have been developed by
the American Diabetes Association. 3 These guidelines include self-monitoring of blood
glucose (SMBG) four times daily if insulin therapy is used to treat the disease, or
(SMBG) two times daily if insulin therapy is not a treatment modality. 3
Previous research has demonstrated that SMBG is essential for achieving
clinically acceptable hemoglobin A 1c levels.

45
·

The DCCT proved that low hemoglobin

Ale scores directly correlated with a decrease in the complications of diabetes mellitus. 2
In essence, SMBG is believed to have a direct and positive effect on blood glucose that
translates into reduced morbidity and mortality for those with the disease.

3
Despite recommendations for SMBG from the American Diabetes Association
and the DCCT tri\1, most people diagnosed with diabetes are not monitoring blood
glucoses as frequently as recommended. 6 Because SMBG is recognized as an effective
and important treatment, causes for decreased SMBG in people with diabetes have been
studied.
Deterrents to SMBG have been hypothesized to include the pain associated with
SMBG and the financial burden associated vvith SMBG.

78
·

However, the extent each

barrier plays has yet to be outlined.
The financial burden of purchasing blood glucose monitoring strips can be
immense. Not all people with diabetes have an insurance provider that covers the entire
cost of strips. Therefore, it is likely that the economic drain plays a major role in
decreasing testing frequency.
Advances in technology have resulted in blood glucose monitors that require
approximately one-tenth the amount of blood that traditional finger-stick blood glucose
monitoring systems require. These new monitoring devices allow for decreased depth in
lancing devices to draw blood. In addition, blood may be obtained from sites other than
finger-tips. Forearm testing, possible with the new, alternative-site meters, permit testing
in locations with fewer nerve-endings per square centimeter. In summary, new,
alternative-site meters potentially allow for decreased pain and possibly increased
SMBG.
We aimed to outline some factors that may significantly affect frequency of
SMBG. The purpose of this research was four-fold:

4

1) To determine if pain associated with SMBG was decreased using an

alternat~e-site meter as opposed to a traditional finger-stick meter.
2) To determine if patients with diabetes had increased SMBG using an
alternative-site meter as opposed to a traditional finger-stick meter.
3) To determine if providing free SMBG strips increased testing frequency.
4) To determine the effects of an alternative-site meter on hemoglobin Ale
measurements.
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CHAPTER II
ALTERNATIVE-SITE GLUCOSE TESTING: A CROSSOVER DESIGN

1

Abstract

A crossover design study was conducted to determine if reducing pain, by using
alternative sites off the finger tip, would increase testing frequency and improve clinical
outcome as measured by hemoglobin A I c (HbA 1c). Subjects with type 1 and type 2
diabetes tested with the FreeStyle meter (group 1) or tested with their original meter
(group 2). After three months the subjects used the alternate meter. Testing frequency
and blood glucose concentrations were recorded for the month before the study began
and monthly thereafter. HbA 1c was tested initially, at the crossover point, and at study
conclusion. Insulin users increased testing frequency from 2.4 to 3.0 tests/day. Testing
frequency for non-insulin users remained the same at 1.5 tests/day. Testing frequency
was the san1e with the FreeStyle and the original meters. The average HbA 1c was 7.4%
(SD 1.5%) initially, 7.3% (SD 1.5%) at the crossover point, and 6.9% (SD 1.1%) at study
conclusion. There was no significant difference in HbA 1c measurements between meter
types. Preference rankings were 76% for FreeStyle, 20% for their original meter, and 4%
preferred both meters equally. This population tended to be in good glycemic control
with 70% having HbAlc at 8.0 at study initiation. Subjects prefened testing with the
FreeStyle meter (76%), but did not increase testing frequency . Study participants tended
to be in good testing compliance and glycemic control with little room for improvement.

1

Bennion N, Christensen NK, McGarrough G. Alternative site glucose testing: a crossover design.
Diabetes Technology and Therapeutics. 2002; 4(1):25-33 .
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Introduction

The American Diabetes Association reported in an October 1998 statistical report
that diabetes mellitus affects 15.7 million people in the United States, comprising almost
6% ofthe population (8.2% of the total population over age 20, and 18.4% over age 65,
with a distribution of 7.5 million men and 8.1 million women).' This disease is
characterized by insulin insufficiency, lack of insulin production and/or resistance to
insulin. Lack of control leads to hyperglycemia and is associated with a variety of
serious complications, including retinopathy, neplu·opathy, neuropathy, and
cardiovascular disease.
The cost associated with diabetes in the United States was $98 billion in 1997. 2
This includes $44.1 billion in direct costs and an additional $54 billion in indirect costs
due to disability and mortality. Improvement in diabetes control, which can be measured
in hemoglobin A 1c (HbA 1c) levels, decreases the complications of diabetes. Gilmer and
O'Conner3 report a 1% improvement in HbA1c level from 10% to 9% was associated
with a $4,116 ± 1,178 difference in cost over 3 years, and a HbA 1c improvement from
9% to 8% had a reduction of cost by $3,090 ± 960. Increasing the frequency of selfmonitoring of blood glucose values resulted in an improvement (lowering) ofHbA1c
levels. A linear relationship between the number of strips used and a decrease in the
HbA1c level in type 1 patients had been reported. Evans 4 reported that the total number
ofreagent strips dispensed reduced HbAlc levels by 0.7% for every extra 180 test strips
in a 6-month period. In a 6-month period, 180 strips would be one blood glucose reading
per day.

8
The importance of normoglycemia for the prevention of diabetic complications
is recognized.

5

S~lf-monitoring of blood glucose (SMBG) has been recommended as a

technique for control of blood glucose and should be an integral part of the treatment
plan. Despite the clear benefit of glucose monitoring in the successful treatment of
diabetes, patients are reluctant to comply with testing regimens. In a study conducted in
Scotland to determine the number of glucose monitoring strips that were dispensed from
the pharmacy compared to the records for prescriptions, only 20% redeemed enough
4

reagent strips to test daily. There were 16% (128) of the 807 type 1 patients who did not
obtain any reagent strips and only 1% (8) who obtained enough strips to test four times
per day. For the 258 patients with type 1 diabetes that had a recorded HbA 1c, only 152
(59%) had obtained at least one packet of reagent strips. Similarly 170 ofthe 290 (59%)
of type 2 patients with a recorded HbA 1c obtained one packet of reagent strips. This
corresponds to data obtained from the National Health Interview Study conducted in the
United States on the frequency of blood glucose testing by Harris.

6

The results showed

only 40% of type 1 and 26% of type 2 taking insulin tested their blood glucose at least
once daily. There were 21% of type 1 and 47% of type 2 patients who did not test their
own blood glucose. Only 5% of type 2 (not on insulin) tested their blood glucose daily.
Diabetes, unlike many other diseases, is a self-management disease. Because
nearly 95% of the required care falls upon the patient, satisfaction and comfort of the
blood glucose monitoring method are pertinent issues in diabetes treatments. Low
7

adherence to diabetes regimens is likely due to multifactorial causes. Rodin summarizes
that one cause of low adherence rates occurs because the treatment for diabetes is

9

complex, intrusive, and inconvenient. Therefore, much focus in diabetes care has tumed
towards less painlul and intrusive means of testing blood glucose.
8

Loveland reported a significant increase in satisfaction score from study
participants who compared the traditional finger-stick method with the less painful thumb
stick method. Carle/ also found a small decrease in pain felt by study participants who
compared the thumb stick method of testing blood glucoses with a method using the ear
lobe to test. While testing on the ear lobe may be less painful, for many patients this

° Fortunately, advances in technology have

method is inconvenient and not practical. 1

shown forearm glucose testing is an accurate and realistic alternative to finger-stick or

· k s1·tes 10r
c g 1ucose testmg.
· II ·12
even t1mm b-st1c
The FreeStyle™ monitoring system requires a very small drop of blood, 0.3 mL,
which allows testing from areas with much lower blood perfusion than the fingertips.
Forearm, upper arm, hand, thigh, and calf are approved alternate sites for testing with the
FreeStyle meter, and the paucity of pain receptors at these alternate sites allows glucose
testing with reduced pain. Our study comparing the FreeStyle monitor to subjects' current
finger-stick monitor was designed to show that patients using alternative site meters may
benefit from an increase in frequency of testing and improved HbA 1c scores. We also
aimed to show that, given a choice, most diabetic patients would prefer to use an
altemative site meter as opposed to a traditional finger-stick meter.

10
Materials and Methods

'
Participants were recruited from the Utah Valley Diabetes Management Clinic
where general guidelines for patient care include instructing patients to check blood
glucose with a meter four times each day if insulin therapy is used and two times each
day if insulin therapy is not used. Approximately 900 notification letters concerning the
study were mailed out to patients who had at one time been a patient at the Utah Valley
Diabetes Management Clinic. Requirements to be a study participant included a
diagnosis of type 1 or type 2 diabetes mellitus, having a meter with a programmable
memory, and being 18 years or older. All study participants used a finger-stick meter
when not using the FreeStyle meter.
A cross-over study design was selected. Study participants were matched by (a)
gender; (b) age; (c) duration of diabetes; and (d) use of insulin therapy or lack of and
separated into two groups. Groups 1 and 2 of matched participants had initial HbAlc
averages of7.3 and 7.6, respectively . Those in gro up one were given the FreeStyle meter
to use for three months; the second group was instructed to use their own personal meter.
After 3 months of study, participants in group 1 placed their FreeStyle meter in a holding
box at the clinic and were instructed to use their own personal meter. The second group
was given the FreeStyle meter to use . The duration of the study totaled 6 months.
Participants in the study attended monthly classes at the clinic during which four
different topics pertaining to nutrition and diabetes were discussed. The class sizes
consisted of2-15 study participants. During the class, participants' meters were
downloaded for the previous month 's readings, and participants received test strips to use

11

during the upcoming month. Those in the study on insulin therapy received 125 strips
monthly; those in'the study not using insulin therapy received 75 strips monthly.
Participants were given the same number of strips tlu·oughout the study and were not
rewarded or penalized for testing more or less frequently than the clinic's
recommendations. Meter downloading consisted of recording the number of times each
study participant checked his or her blood glucose with the meter they were instructed to
use during the previous month . The range of the readings and the monthly average and
standard deviation were also recorded from the meter downloads. HbA 1c measurements
perfonned on a DCA 2000 Analyzer Model 5031 C (Bayer Corporation, Elkhart, IN) were
recorded for each study participant at the beginning of the study, after tlu·ee months (the
time when they switched meters), and at the conclusion of the study (after six months).
At the conclusion of the study, participants were given a questionnaire to record their
meter preference.
Orthogonal regressions were used for all of the correlation analyses conducted in
this study. There are two assumptions that guide this choice of analysis. The first is that
there is measurement error in both the x andy axes of the correlation. The second is that
the magnitude of the error is approximately proportional to the magnitude ofthe
measurement. An orthogonal regression is the proper statistical approach when the first
situation exists, and the 011hogonal regression can be manipulated to accommodate the
second situation.

12
Results and Discussion

'
A total of 121 subjects (average initial HbA1c of7.48%) began the study. By the
crossover point, 17 subjects dropped out of the study (average initial HbA1c of7.72%)
leaving 104 subjects (average crossover HbA1c of7.28%). Another 12 subjects did not
participate in the final HbA1c test (average crossover HbA1c of7.58%) which left 92
subjects (average crossover HbA1c of7.24%) who completed the study. Ofthese
subjects 62 were insulin users and 30 were non-insulin users ; 62 used the arm
exclusively as the test site when using FreeStyle; 16 used the arm and the finger, and 14
used the finger exclusively . Many subjects withdrew from the study because they moved
away from the study location. The average age of those completing the study was 53.7
years, and the distribution of ages and insulin use is shown in Figure 1. A small subset of
the population was younger than 40 years, but the large majority of the population was
40-80 years old.
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Some general trends were observed over the course of the study. Average
values for HbA1~, glucose, and testing frequency for the insulin users and non-insulin
users are listed in Table 1. The relationship between the HbA 1c measurements and the
average glucose is shown in Figure 2.
The expected relationship was exhibited: the HbA1c was directly proportional to
the glucose measurement with a con·elation coefficient of0.68 for insulin users and 0.74
for non-insulin users. The subjects using insulin increased their testing frequency during
the study, while the non-insulin using population did not (Table 1).
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TABLE 1. Overall trends in testing parameters over the course of the study.
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(/(',;//di'.lf)

!50

2A

'7 .6

lHO:l

3 .1

7.2

<O.OJOP

153
l5.J

('";,!

7.7

ln.iti.1l
J months
6 rnonti"L-;
lniti .1 l
3 nwnths
6 rnontl"Ls

Noninsulin

Clw:o~c

p "·d lie·'

I II> A1c

IJ.j

2.9
1.5
1.6

12.'i

1 .4

127

6.0

6.6

<O.D.l:C'
< O.OJS·'

63

p 1•,tlrw
<0.000 1·'
<0.000 1·'

<0.003'
O.D7

a We reject the null hypothesis of no significant difference in means, when the p value of
the test is less than the significance level of a= 0.05.

Of the 92 subjects responding to a questionnaire at the end of the study asking
their meter preference, 76% preferred FreeStyle, 20% prefened their original meter, and
4% preferred both meters equally. The testing frequency with FreeStyle is plotted versus
the testing frequency with the users' original finger-stick meter (during the study) in
Figure 3.
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On average, the difference in testing frequency between FreeStyle and the
original meter w~ too small to be clinically relevant: 2.45 test/day with FreeStyle and
2.52 tests/day with the original meter. The meter preference had no influence on testing
frequency. Apparently, providing a preferable monitor for glucose testing is not
sufficient to increase testing frequency. The influence of using an alternate test site on
clinical outcome was assessed by comparing HbA 1c results for the 78 subjects who used
the arm testing site for FreeStyle, either exclusively or part of the time. The change in
HbAlc is shown for FreeStyle and the subjects' original meters in Figures 4 and 5 .
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The average HbA1c was 6.93% when the FreeStyle was used on the arm test site
and was 7.08% when the finger-stick meter was used. The difference is not statistically
significant (p value= 0.093 versus a significance level of a= 0.05). In general, the
choice oftest site did not have an influence on the clinical outcome as measured by
HbA 1c. There were four cases where there was a substantial change in HbA 1c over the
course of the study as indicated by the numerals 1-4 on Figures 4 and 5. The study data
for these subjects are listed in Table 2.
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TABLE 2. Subjects who experienced a substantial change in HbA 1c over the course
ofthe study.
St~bjccl
Slr:d_l! J'Oill! ( lf,'lHt.'h)
u
J
2
.l
.f
s
HbAk(",)
AverJge• g1uccJ~c' (mg / dL)
Frequency (tcsts / d<Jy)
2

3

4

!> . .!

d.Jt.1
:--Jo d.1t.1
:--.ill

134

0.6

1.3

1.-1

27 5

291

2.5

2 .7

10.0
158
3.3

1.6

11"

11.2

HbAk("·;,)
Av erJge glucose (mg / dl.)
Frequency (tcsts/d<Jy)

N o dJt.1
N0 dJt<J

HbAlc (';:,)
AverJge glucose (mg/dL)
Frequency (tests/d.1y)

12.2
No dJt.1
No dJt,1

HbA1c (' ),)
gluc"(''L• (mg / dl..)
Frequency· (tc,tsj,i,,y)

108
I. \I

Aver.1gc~

7.-1
16\J

172

6
5.8

1:! 0
2.2

137

2
6.6

1t6
2.6

126
2.6

11.8

·toll
2.7

:!69
0.9

312
0.6

no d.1t.1
no d.1t.1

232
0.1

208
0.2

9.2
161
0.4

1:!9
0.5

135

6
13'!

184

20'i

9.2
254

1.'1

1.'1

1.8

5.2
2.1

2.2

The entries in bold type indicate results obtained with the FreeStyle system.

The average glucose for subject 1 decreased in the second half of the study while
the subject used FreeStyle with an increased testing frequency. Subject 2 had a steady
decrease in glucose average over the course of the study; the testing frequency with both
meters remained constant. Subject 3 experienced a decrease in average glucose in the
second half of the study, but the testing frequency during this period decreased
substantially when the subject crossed over from using FreeStyle to using their original
meter. Subject 4 experienced a substantial increase in glucose average in the second half
of the study using their original meter with no significant change in the testing frequency.
There is no consistent pattern of testing frequency or meter used that would explain the
HbA 1c changes for these four subjects.
In recent literature there has been discussions as to whether or not differences in
glucose readings for off-finger tests would have a detrimental effect on glucose
control. 13 •14 There was an average improvement in glucose control for subjects who used
FreeStyle on the arm testing site as measured by the modest improvement in the HbA1c
over the course of the study (7.29% to 6.93%). The meter used did not have an influence

- -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - - - - - -
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on this result. The only case of a substantial increase in I-IbA 1c occurred when the
original finger te~ meter was in use (subject 4). There were no significant adverse events
reported in the study when either arm testing or finger testing was used.
It was originally thought that less painful glucose testing would encourage an
increase in testing frequency. Although 76% of the subjects preferred the FreeStyle
system to the finger stick device they were accustomed to using, this did not translate into
more frequent testing. The population of this study, however, might not have been ideal
for testing this hypothesis. The degree of glycemic control for this population was quite
good with 42% of the prestudy HbA 1c tests of 7.0% or below, and 29% between 7.1 and
8.0%. This left only 30% of the population for which a change in therapy was necessary.
Perhaps a more realistic approach to testing the hypothesis is to determine whether
patients would be willing to undergo more aggressive treatment, which would require
more frequent testing, if a less painful testing alternati ve were available.

Conclusion

A large majority of the subjects (76%) preferred the FreeStyle meter over the
finger-stick meter they were using when the study began; 20% preferred their original
finger-stick meter, and 4% prefened both meters equally. The preference for the
FreeStyle meter did not lead to an increase in testing frequency with this meter. There
was an average increase in testing frequency among insulin users for all meters, and there
was also an average improvement in HbA 1c tests among all pm1ici pants. The change
from a finger to an off-finger glucose test had no net effect on glycemic control as
measured by HbA 1c.
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CHAPTER III
ALTERNATIVE-SITE BLOOD GLUCOSE MONITORS AND COST OF STRIPS:
THE EFFECTS ON METER PREFERENCE AND PAIN RATING, TESTING
FREQUENCY AND GL YCOSYLATED HEMOGLOBIN.

Abstract

A 6-month study providing free testing strips was used to compare testing
frequency and glycosylated hemoglobin of participants given an alternative-site meter.
Thirteen months later a final glycosylated hemoglobin measurement, testing frequency,
and a questionnaire regarding meter preference and pain rating were obtained. Seventysix percent of participants preferred the alternative-site meter, which was rated as
significantly (p < .05) less painful. Testing frequency significantly improved (p = .001)
while free strips were be ing provided. Testing frequency thirteen months later was not
significantly different from the baseline testing frequency (p

=

.101). Hemoglobin Ale

was significantly lower 6 months after the study began (p = .000) and 13 months later (p

= .008) than the baseline hemoglobin A 1c. We conclude that: 1) patients in our study
preferred the alternative-site meter; 2) patients in our study experienced a positive effect
in hemoglobin Ale measurements; and 3) cost of strips does play a role in testing
frequency.

22
Introduction

'
Diabetes Mellitus, a disease with many long-term debilitating effects, is expected
to increase in incidence in the United States. 1 Because diabetes is a growing epidemic,
treatment of the disease will have an ever-increasing impact on Americans.
The Diabetes Control and Complications Trial proved a direct relationship
between glycosylated hemoglobin measurements (HbA 1c) in diabetic patients and the
development of diabetic complications? Reduction in HbA 1c, and thus the
complications of diabetes, is dependent on the management of medical nutritional
therapy, routine exercise and medications.
The goal of diabetes management is to achieve normoglycemia.

Self-monitoring

ofblood glucose (SMBG) is considered to be an essential step in maintaining
normoglycemia. Karter 3 reaffirmed the importance of SMBG. Using a cohort study
design, Karter 3 showed that SMBG in type 1 diabetics at a frequency greater than or
equal to 3 times per day and daily for type 2 diabetics was significantly associated with
lower HbAlc levels. 3 These findings support the clinical recommendations suggested by
the American Diabetes Association. The majority of diabetics, both type 1 and type 2, do
not test blood glucose daily. 4 A follow-up study, associating the frequency of SMBG
with HbA 1c, conducted by Anderson 5 found that increasing the frequency of selfmonitoring of blood glucose was followed by a decrease in HbA 1c levels. Identifying
factors that motivate or increase SMBG are, consequently, important steps red ucing the
morbidity and moiiality related to diabetes.
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There are many impeding factors responsible for the insufficient frequency of
blood glucose m6nitoring. These inhibitors include emotional, physical, social, and
6

environmental. Jones concluded that people with diabetes who li sted the fewest barriers
to self-monitoring of blood glucose are more likely to check blood glucoses. However,
determining the extent each barrier plays is yet to be outlined. Psychological and social
factors relating to SMBG have been studied. 7 Other factors that may have influence on
testing frequency and HbA I c include the monitoring device and pain associated with
monitoring as well as the expense of blood glucose monitoring.
Traditional finger-stick blood glucose moni toring systems do cause some pain and
finger soreness. Recent advances in technology have produced alternative- site blood
glucose monitoring systems that use less blood and allow for blood samples to be
obtained from sites less painful than finger sticks. In creased satisfaction has been
reported with a decrease in pain when a site with fewer nerve endings than the fingertips
was used for SMBG. 8
The financial barriers that face those with diabetes are large. Medications and
blood glucose testin g strips add to the expense of the disease, especially to those without
insurance coverage. Because blood glucose testing, requires the patient to use strips,
purchasing strips may influence the patient to test le:ss frequently, avoiding higher
economic expenditure on testing strips.
The purpose of this study was to determine: 1) if pain and meter satisfaction play
a role in the frequency of SMBG; 2) if providin g a !tess-painful monitoring system would
decrease HbAlc ; and 3) if the cost oftesting strips had an effect on SMBG.
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Methods and Statistics

'
A cross-over study design was chosen for the initial study using patients from
Utah Valley Diabetes Management Clinic. Those who participated in the study were
recruited via a notification letter sent to all patients of the Utah Valley Diabetes
Management Clinic. Study participants were limited to patients 18 years of age or older
with a diagnosis of type 1 or type 2 diabetes mellitus and trained to use a program-able
blood glucose meter capable of being downloaded in the clinic.
The cross-over design consisted of two matched groups. Study participants were
matched by gender, age, duration of diabetes, and use of insulin therapy. Although the
two groups were not matched by initial HbAlc levels, the initial HbAlc levels were 7.3%
for group one and 7.6% for group two. Group one began the study using the FreeStyle
alternative-site meter. Group two began the study using their own finger-stick meter.
After three months, study participants in group one placed their FreeStyle meter in a
holding box at the clinic and were instructed to use their own personal meter while the
second group was given the FreeStyle meter to use. The duration of the study totaled 6
months. Thirteen months after the initial study began and 7 months after the study
ended, all subjects that completed the study were asked to participate in a follow-up study
visit.
The Therasense FreeStyle meter was used as the alternative-site meter in the
study. This meter requires a very small drop of blood (0.3 fll) which allows testing from
areas with much lower blood perfusion than the tingertips. Forearm, upper arm, hand,
thigh, and calf are FDA approved alternate sites for testing with the FreeStyle meter.
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While using the FreeStyle meter, patients were instructed to try using a site other than
their fingers, but ~ere not excluded from using their fingers.
Throughout the six-month study, participants met monthly in groups ranging from
2 to 15 participants. Four of the monthly meetings consisted of a 30 minute nutritional
education session. Topics included reducing LDL cholesterol through dietary practices,
dining at restaurants on a diabetic diet, non-nutritive sweeteners, and estimating portions
sizes correctly. The other monthly meetings were dedicated to teaching the use of the
alternative-site meter or to collecting the study data (height, weight, downloading meters
and providing a copy of the results to the patient). At each monthly meeting, participants
were given 75 test strips if they were not using insulin therapy and 125 test strips if
insulin therapy was used. Patients were not penalized if they did not use all of the strips
given at the previous month 's meeting. Test strips were specific to the meter the patient
was using during the upcoming month. The patients incuned no cost for test strips.
During each monthly meeting, participants' meter readings were downloaded and
the nwnber of blood glucose tests for the previous thirty days was recorded. HbA 1c
measurements were recorded for each study participant at the beginning of the study and
at the conclusion of the study (after 6 months).
The third objective of this study (the cost effect of strips for SMBG on testing
frequency) was assessed by re-contacting the original study participants for a follow-up
HbAlc and to answer a questionnaire regarding meter preference. Participants were
asked, through a formal questionnaire, to rate the pain they felt using the alternative-site
meter and their original meter on a scale of I to 10 ( 1 being the least pain and 10 being
the highest pain). Participants were also asked to list their meter of preference. A paired

26
t-test comparing the pain rating between the two meters was conducted. A repeated
measures ANOVA was used to evaluate monthly testing frequency comparing the prestudy testing frequency, the 6 1h month testing frequency (conclusion of the initial study),
and the 13th month testing frequency (7 months after the initial study concluded). Again
using a repeated measures ANOV A, pre-study HbA 1c scores, 6th month HbA 1c scores
and 13 1h month HbAlc scores were evaluated.

Results

A total of 121 participants began the initial study, with 92 pa11icipants still
1

enrolled at the 6 h month mark. Fifty-nine participants returned for the follow-up
questionnaire and HbA 1c at the 13th month follow-up . Of those study participants who
returned for the follow-up study, 57% were male. Seventy-six percent of those returning
after the sixth-month study were using insulin therapy to treat their diabetes mellitus.
The pat1icipants ranged in age from 21 years to 78 years old. The alternative-site meter
was preferred by 74% of the participants who answered the questionnaire. Pain scores
were significantly (p < .05) less for the alternative-site meter compared to the original
finger-stick meter. The standard deviation was 2.5.
Using a repeated measures ANOVA, we compared the SMBG monthly tests for
1

participants at the beginning of the study, 6 months later, and at the 13 h month time
frame. The frequency of monthly testing significantly (p = .001) increased after 6
months. However, there was a decrease in frequency of testing between the 6th month
testing frequency and the 13th month testing frequency (p
significant.

=

.128) although not

The SMBG testing frequency, although lower, was not significantly
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different from the SMBG testing frequency at the pre-study stage (p = .1 01 ). The 6th
month and the 13'\11 month HbA 1c scores were both significantly different from the prestudy, initial HbAlc scores (p < .000 and p = .008 respectively). The score for HBAlc
from the 6th and the 13th month marks were not significantly different (p = .34 7).
Participants gave the alternative-site meter an average pain rating of 2.5, significantly (p
< .05) less than the pain rating of 3.5 for their original meter.

Pre-study checks per month averaged 59.83. After the six-month study, the
checks per month averaged 72.17. Thirteen months later testing frequency decreased to
an average of 66.5 checks per month. A significant increase occurred for the frequency
of testing during the initial six-month study. The testing frequency thirteen months after
the study began was not significantly different from the pre-study testing frequency
(Table 3).

TABLE 3. Repeated measures ANOVA for testing frequency .
Comparison of Monthly SMBG

6111 Month SMBG
Pre-Study
SMBG

13th Month SMBG
Pre-Study SMBG

6th Month
SMBG

13th Month SMBG
Pre-Study SMBG

13th Month
SMBG

6th Month SMBG

Significance (p)

.001
.I 01
.001
.128
.1 01
.128

Mean for Monthly SMBG

Pre-Study Mean: 59.83 ±
5.48

6th Month Mean: 72.17 ±
5.65

13 111 Month Mean: 66.53 ±
6.39

*Degrees of Freedom 2; Mean Square 1793.794; Sum of Squares 3587.589
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Initial HbAlc scores averaged 7.5%. After the six-month study HbAlc scores

'
averaged 7.0%. The follow-up study HbAlc scores (one year af1er the initial study
began) averaged 7.1 %. Comparing HbAlc scores at the 6th month point with the baseline
or beginning HbAlc scores and comparing the final (13th month) HbA1c scores with the
baseline HbA 1c scores, we found HbA 1c scores following the study and one year later
were both significantly lower than the initial HbA 1c score. There was a slight, but not
significant, increase in HbA 1c scores from the 6th month mark to the 13th month mark
(Table 4).

TABLE 4. Repeated measures ANOV A for HbA 1c.
Comparison of HbA 1c Scores
6u 1 Month HbA I c
Pre-Study
HbA1c

13th Month HbA1c
Pre-Study HbA 1c

6th Month
HbA1c

13th Month HbA1c
Pre-Study HbA 1c

13th Month
HbAlc

6th Month HbA 1c

Significance (p)
.000
.008
.000
.347
.008
.347

Mean for HbA 1c Score

Pre-Study Mean: 7.469 ±
.171

6th Month Mean : 6.986 ±
.135

13th Month Mean: 7.085 ±
.143

* Degrees of Freedom 2; Mean Square 3.845; Sum of Squares 7.690
Ofthe participants who completed the study, 22 had a HbA1c greater than or
equal to 8.0. Fourteen of those preferred the FreeStyle. Using at-test to compare the
HbA1c at the conclusion of the six-month study for those with the higher HbAlc of
greater than 8 (those with higher average blood glucose readings), to the final HbAlc 13
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months after the study began, there was no significant difference between HbA1c
scores (p = .694).' The standard deviation was 0. 78.

Discussion

During the initial six-month study participants were given free testing strips for
the meter they were using. The decrease in testing frequency in the follow-up study as
compared to the initial study was likely due in part to the absence of free testing strips.
The decrease in HbA 1c through the initial study was expected secondary to the increase
in testing frequency as per study. Likewise the slight, but insignificant increase in
HbA 1c between the

6th

month score and 13 months later was expected with the decrease

in testing frequency. The HbA 1c scores 13 months after the study remained significantly
lower than the baseline HbA 1c scores. There was no difference in HbA 1c between the
6th

month measurement and the l3 1h month measurement for study subjects who had high

HbA1c measurements greater than 8.0% indicating that there was a consistent higher
average blood glucose level in these individuals.
A high drop-out rate occurred because the study spanned a total of 13 months.
Many participants could not be located for the questionnaire and final HbA 1c. Therefore,
this data cannot be generalized for all diabetic patients.

Conclusion

Seventy-four percent of the participants who completed our study preferred the
alternative-site meter. The alternative-site meter was also rated as significantly less
painful. For these study participants, HbA 1c and testing frequency both significantly
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improved from the baseline measurement to the end ofthe study. The decrease in
testing frequency'l3 months after enro ll ing in the study may be attributed to the lack of
free strips and monthly contact with health-care providers. Trento 9 has shown the benefit
of improved glucose control for patients with frequent contact with health-care providers.
Even though this decrease in testing frequency was significantly lower than the testing
frequency at the end of the initial study, the change in HbA1c was not significantly
different seven months later in the follow-up study. These results indicate that this study
had positive and lasting effects on HbA1c .
We conclude that: 1) patients in our study prefetTed the alternative site meter; 2)
participation in this study had a positive effect on HbA 1c; and 3) the cost of SMBG strips
may play a role in frequency of testing.
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CHAPTER IV

'

GENERAL CONCLUSION

At the conclusion of the 6-month crossover study, 76% of the study participants
preferred the alternative-site meter. While both insulin and non-insulin users had
increased testing frequency 3 months after the study began, this increase in testing
frequency was maintained only by the insulin users after 6 months.
Although the alternative-site meter was definitely the prefened meter, testing
frequency was not significantly different between the alternative-site meter and the
traditional finger-stick meter over the initial six-month period. HbA 1c measurements
correlated well (correlation coefficient of0.68 for insulin users and 0.74 for non-insulin
users) with the average blood glucose obtained from the glucose meters. Glycosylated
hemoglobin was not significantly different between the two meter types.
At the 13-month follow-up period, a questionnaire was given to the 59 study
participants. Similar to the preference rating for the alternative-site meter 6 months after
the study began, 74% of the participants rated the alternative-site meter as the meter they
favored. Pain scores were rated as significantly lower for the alternative-site meter as
opposed to participants' traditional meters.
These 59 participants experienced a significant increase in testing frequency at the
6-month mark over the baseline testing frequency. By the 13-month mark, testing
frequency was not significantly different from the baseline testing frequency. HbA 1c
measurement was significantly lower at the 6-month mark as compared with baseline and
remained significantly lower 13 months later from the baseline.
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It is apparent that the alternative-site meter is the meter of preference for most

people with diabcles . This preference is long-term and likely due to decreased pain
associated with the alternative-site meter. Despite being a meter of preference and
reduced pain, the alternative-site did not significantly affect testing frequency or HbAl c.
In essence, reduced pain and increased meter satisfaction is not enough to increase testing
frequency or decrease HbA 1c.
For those who completed the 13-month mark of the study, it was noted that
providing free blood glucose monitoring strips significantly increased testing frequency.
This effect declined when free strips were no longer supplied. The positive effect on
HbAlc seen with the increase in testing frequency after 6 months of free strips and
education was lasting.
We conclude that providing an alternative-site meter improved patient satisfaction
and decreased the pain of self-monitoring blood glucose, but did not affect testing
frequency or HbA 1c. These results were obtained in a population with relatively good
blood glucose control (42 participant I-IbA 1c measurements were less than 7% and 70
participant HbA 1c measurements were less than 8%) and may not reflect what would
influence those with less well-controlled diabetes mellitus. Providing free blood glucose
monitoring strips significantly increased testing frequency only while the strips were
provided. Therefore, provision of free blood glucose monitoring strips is a factor in
increasing blood glucose monitoring for certain patients.
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Appendix A

'
Questi01mairc

Date.______ HbA1 c. _____

Name--------------------------

Meter you are currently using,________________________
Meter you used before the study began _________________
If you are not currently using the Therasense FreeStyle meter state the reason for using
the meter you currently use.
Is there a difference between the meter you are using and the Therasense FreeStyle meter
in any of theses areas? If so, please circle and explain.
A) Insurance co-pay for strips
B) Convenience or ease in testing
C) Familiarity
D) Accuracy
E) Features of the meter
Please rate the pain level of testing with the Therasense FreeStyle meter.
(1 =no pain, 10 =painful).
1
2
3
4
5
6
7
8
9
10
Please rate the pain level of testing with the meter you are currently using if you are not
using the Therasense FreeStyle meter. (I =no pain, 10 =painful).

1

2

3

4

5

6

7

8

9

10

While using the FreeStyle meter, did you feel the meter readings were different from
what you expected. If yes, please describe.

If you could change or improve on the Therasense Freestyle meter, what you changes
would you recommend. Please list.
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